Takeover Defense: Poison Pill and Proxy Contest Strategy

Unocal Corp. .. Mesa Petroleum Co., 493 A.2d 946 (Del. 1985) established intermediate scrutiny standard for defensive measures requiring (1) reasonable belief of threat to corporate policy and (2) proportional response to threat, both subject to enhanced judicial review beyond business judgment rule. Revlon, Inc. .. MacAndrews & Forbes Holdings, 506 A.2d 173 (Del. 1986) imposed duty to maximize stockholder value when sale of company becomes inevitable, shifting board focus from defending corporate independence to obtaining best price. Paramount Communications, Inc. .. QVC Network Inc., 637 A.2d 34 (Del. 1994) clarified that change of control transactions (cash mergers, controlling shareholder transactions) trigger Revlon duties even when board prefers alternative bidder. Moran v. Household International, 500 A.2d 1346 (Del. 1985) upheld board authority to adopt shareholder rights plans (poison pills) without prior stockholder approval, providing foundational authority for modern takeover defense. Our corporate governance practice handles Unocal proportionality analysis, Revlon trigger assessment, and parallel defensive measure validity review at hostile bid emergence.

Paramount Communications, Inc. .. Time Inc., 571 A.2d 1140 (Del. 1990) confirmed "Just Say No" defense viability when board pursues coherent long-term strategy and rejects hostile bid without putting company up for sale, distinguishing Revlon inapplicability. Air Products and Chemicals, Inc. .. Airgas, Inc., 16 A.3d 48 (Del. Ch. 2011) upheld 14-month poison pill defense despite premium hostile bid, applying Unocal standard with deference to board strategic vision. Williams Cos. Stockholder Litigation 2021 invalidated COVID-era poison pill as preclusive defensive measure exceeding Unocal proportionality, highlighting Delaware Court of Chancery's continued scrutiny of pill design. Board independence (majority outside directors), thorough deliberation process, and independent financial advice provide strong defenses to enhanced scrutiny analysis with substantial procedural documentation requirements. Our board of directors meetings practice handles board deliberation documentation, independent director engagement, and parallel financial advisor coordination across defensive measure adoption.

Shareholder rights plans (poison pills) issue rights to existing shareholders permitting purchase of company stock at significant discount (typically 50%) when triggering acquirer exceeds 10-15% beneficial ownership threshold without board approval. Flip-in pill dilutes hostile acquirer's position by allowing all other shareholders to purchase discounted stock, making continued acquisition economically prohibitive without negotiation. Flip-over pill applies to merger consideration after hostile takeover, allowing target shareholders to purchase acquirer's stock at discount, extending dilution into post-merger context. Versata Enterprises v. Selectica, 5 A.3d 586 (Del. 2010) upheld low-trigger pill (4.99%) for NOL preservation purposes, demonstrating flexibility for tax attribute protection contexts. Our corporate governance counsel practice handles poison pill design, trigger threshold analysis, and parallel adoption timing strategy across hostile threat response.

Proxy contests challenge incumbent board through alternative director nominations with formal solicitation under SEC Rule 14a-9 (false or misleading statements prohibition) and Schedule 14A disclosure requirements. SEC Universal Proxy Card rule (effective September 1, 2022) requires both company and dissident to use single proxy card listing all nominees, enabling shareholders to mix and match nominees rather than choosing one slate entirely. Advance notice bylaws require dissidents to provide stockholder nomination notice 90-120 days before annual meeting with detailed disclosure of nominee qualifications, beneficial ownership, and arrangements. Proxy advisory firms (ISS, Glass Lewis) recommendations significantly influence institutional investor voting with proxy fight outcomes often determined by their analysis. Our corporate governance advisory practice handles proxy contest defense, Universal Proxy Card strategy, and parallel ISS/Glass Lewis engagement across activist campaigns.

Schedule 13D filing under Securities Exchange Act § 13(d) requires beneficial owners of 5%+ of registered equity to file within 10 days disclosing identity, source of funds, purpose, and any arrangements with others (Item 6 disclosure). Recent SEC amendments (effective February 2024) shortened 13D filing window to 5 business days, accelerating activist disclosure timeline and reducing accumulation periods. Schedule 13G short-form filing available for passive investors (qualified institutional investors, exempt investors with no control intent) with quarterly amendments rather than 10-day prompt updates required for 13D filers. Wolf pack activism (coordinated activity by multiple investors) creates group filing obligations under § 13(d)(3) with substantial penalty exposure for failure to disclose coordinated activity. Our board oversight failures practice handles 13D monitoring, wolf pack detection, and parallel activist engagement strategy across investor relations programs.

Hart-Scott-Rodino Antitrust Improvements Act (15 U.S.C. § 18a) requires premerger notification to DOJ and FTC for transactions exceeding size-of-transaction threshold ($119.5 million in 2025) with 30-day waiting period for cash tender offers and 30-day initial waiting period for other transactions. Tender offers under Williams Act § 14(d) require Schedule TO filing by bidder with offer price, financing source, and material terms, with target Schedule 14D-9 response within 10 business days containing recommendation. Best price rule under SEC Rule 14d-10 requires same consideration to all tendering shareholders during tender offer period, eliminating preferential treatment for early or large tenders. All-holders rule requires tender offer open to all holders of subject class with limited exceptions for non-US shareholders subject to foreign law restrictions. Our merger clearance practice handles HSR Form filing, tender offer Schedule TO/14D-9 coordination, and parallel antitrust review strategy across cross-border takeover defense.

Delaware Court of Chancery provides primary forum for stockholder challenges to defensive measures through expedited proceedings allowing rapid pre-closing review of board action under Unocal/Revlon framework. Direct claims (challenging breach of fiduciary duty causing direct harm to stockholders) and derivative claims (on behalf of corporation for corporate harm) create substantively distinct standing requirements and procedural posture under Tooley v. Donaldson, Lufkin & Jenrette, 845 A.2d 1031 (Del. 2004). Aronson v. Lewis, 473 A.2d 805 (Del. 1984) demand futility analysis (refined in Zuckerberg v. Facebook 262 A.3d 1034, Del. 2021) governs derivative claim pre-suit demand requirement with substantial pleading specificity demands. Books and records demands under DGCL § 220 enable stockholder investigation of board action before filing breach of fiduciary duty claims, with Disney v. Walt Disney Co. Derivative Litigation framework for proper purpose review. Our breach of fiduciary duty practice handles Delaware Court of Chancery defense, Aronson demand futility analysis, and parallel § 220 books and records response across stockholder challenges.

Schedule 14D-9 (target response to tender offer) must be filed within 10 business days of bid commencement containing board recommendation, reasons for recommendation, and required disclosure of any material agreements or arrangements. SEC Rule 14e-3 prohibits trading on material non-public information about tender offers, creating insider trading liability for both bidders and targets with substantial penalty exposure. Schedule 14D-9 disclosure litigation frequently challenges target's recommendation as inadequate disclosure of merger consideration analysis, conflicts of interest, or material financial projections affecting shareholder voting decision. Recent disclosure-only settlements scrutinized post-Trulia v. In re Trulia Stockholder Litigation, 129 A.3d 884 (Del. Ch. 2016) with Delaware Court of Chancery requiring plainly material disclosures for class action settlement approval. Coordinated M&A litigation defense manages Schedule 14D-9 disclosure analysis, Trulia disclosure-only settlement positioning, and parallel federal securities class action coordination across tender offer disputes.